1. Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240. Issue 6 (24th November 2020) Authors: Ryoo, Baek‐Yeol; Merle, Philippe; Kulkarni, Amit S.; Cheng, Ann‐Lii; Bouattour, Mohamed; Lim, Ho Yeong; Breder, Valeriy; Edeline, Julien; Chao, Yee; Ogasawara, Sadahisa; Yau, Thomas; Garrido, Marcelo; Chan, Stephen L.; Daniele, Bruno; Norquist, Josephine M.; Chen, Erluo; Siegel, Abby B.; Zhu, And... Journal: Cancer Issue: Volume 127:Issue 6(2021) Page Start: 865 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Issue 7 (July 2021) Authors: Galle, Peter R; Finn, Richard S; Qin, Shukui; Ikeda, Masafumi; Zhu, Andrew X; Kim, Tae-You; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed; Li, Daneng; Mulla, Sohail; Verret, Wendy; Xu, Derek-Zhen; Hernandez, Sairy; Ding, Beiying; Liu, Juan; Huang, Chen; Lim, Ho Yeong; Cheng, Ann... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 991 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10064 (7th January 2017) Authors: Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang; Bodoky, György; Pracht, Marc; Yokosuka, Osamu; Rosmorduc, Olivier; Breder, Valeriy; Gerolami, René; Masi, Gianluca; Ross, Paul J; Song, Tianqiang; Bronowicki, Jean-Pierre; Ollivier-Hourmand, Isabelle; Kudo, Masatos... Journal: Lancet Issue: Volume 389:Issue 10064(2017) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗